The Insurance Locator

Report Description

The impending expiry of several biopharmaceutical products patented and successfully growing demand for patients, insurance companies and government agencies to reduce drug costs have created numerous opportunities in the global market for biosimilars. The market biosimilars world is expected to be worth U.S. 19.4 billion U.S. dollars in 2014, growing at a CAGR of 89.1% from 2009 to 2014. Biosimilars market is segmented peptide, glycosylated recombinant proteins, glycosylated recombinant proteins, and others.

The main factors driving the market demand of biosimilars are increasing user acceptance, low costs and general application area, increasing government initiatives, and emerging India and The economies of China. The main challenges for the market for biosimilars are the risks involved with investment and the possible failure of the drug during the stages of development. However, biosimilarss opportunities for the market is immense, and biological worth U.S. 25 billion U.S. dollars will have patent protection in 2016, and a way of approval in U.S. will open the largest potential market.

Asia early marketing and high absorption rate biosimilar products become the dominant market in 2008 with 34.1% share of the worldwide market for biosimilars. The U.S. market is expected to dominate in 2014 after the U.S. market opens in 2010. Currently, the global biosimilars market is highly fragmented, with major players like Biocon, Dr. Reddy's Laboratory, INTAS, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva and Wockhardt. Favorable regulatory developments in the field of biosimilars are expected to increase market share and profit margins while reducing medical costs.

Scope of Report

This report aims to identify and analyze market biosimilars based on products, services, technology, and applications.

• The market for biosimilars
Peptides, glycosylated recombinant proteins, glycosylated recombinant proteins, and other

• Biosimilars Market services
Research Contract and manufacturing services, clinical services

• Biosimilars market applications
Oncology, infectious diseases, chronic autoimmune and other diseases

• The technology market Biosimilars
Recombinant DNA technology, monoclonal antibody technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance and mass spectrometry

Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and the prospects of competition. This report will also provide more market of 60 tables for different geographic regions covering the sub-sectors and micro-markets. In addition, the report also offers 40 company profiles for each of its sub-sectors.

What makes our reports only?

• We offer the longest in the market segmentation of the chain in this sector-not many reports provide market breakdown to level 5.
• Each report is approximately 250 pages with over 100 tables of market data, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
• No single report by any other publisher provides market data for all product segments namely, services, applications, components, technology, and stakeholders in a single report for all four geographic regions – U.S., Europe, APAC, ROW (Rest of World).
• We offer 10% of customization. It is generally acknowledged that customers can not find a specific market intelligence you seek. Our personalization will ensure that intelligence necessarily get market and we are looking for a loyal customer.
• 15 pages of high-level analysis, including benchmarking strategies, best practices and the market for cash cows (BCG matrix). We conducted detailed market positioning, product positioning and competitive positioning. Entry strategies, identified gaps and opportunities for all stakeholders.
• Analysis of global market for the following sectors: pharmaceuticals, devices medical, biotechnology, semiconductors and electronics, energy and energy supplies, food and beverages, chemicals, advanced materials, industrial automation and telecommunications and IT. We also analyzed the super-retailers and retailers, technology providers and research and development (R & D) companies.

Key questions answered

• What are the segments with high growth / cash cows and how market segmentation in terms of applications, products, services, ingredients, technologies, and stakeholders?
• What are market estimates and forecasts, the markets are doing well and which not?
• Where are the gaps and opportunities, what is driving the market?
• What are the key playgrounds? What are the imperatives margin of victory?
• How is operational and product pipelines? Who's Doing What?

Powerful Research and Analysis

Analysts work of renowned publishers and market research companies, worldwide, adding his experience and domain knowledge. We get the facts from more than 22,000 sources of news and information, a huge database of key industry participants and leverage our relationships with over 900 research firms market worldwide. We inspired to help our customers grow by providing quality business ideas with our vast repository of intelligence market.

For more information, visit:

target = "_blank" href = "http://www.aarkstore.com/reports/Biosimilars-2009-2014–29843.html"> http://www.aarkstore.com/reports/Biosimilars-2009-2014–29843.html

Or send an email to press@aarkstore.com or call +919272852585

About the Author:

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.

Article Source: ArticlesBase.com – Biosimilars (2009 – 2014)

2009 Saturn Outlook